Sorrento Therapeutics, Inc.
SRNE · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $15,025 | $16,251 | $15,594 | $17,400 |
| % Growth | -7.5% | 4.2% | -10.4% | – |
| Cost of Goods Sold | $8,453 | $5,186 | $13,722 | $8,268 |
| Gross Profit | $6,572 | $11,065 | $1,872 | $9,132 |
| % Margin | 43.7% | 68.1% | 12% | 52.5% |
| R&D Expenses | $33,271 | $43,805 | $41,044 | $67,989 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $48,941 | $54,980 | $39,464 | $50,159 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1,593 | -$76 | $1,129 | $1,127 |
| Operating Expenses | $83,805 | $99,912 | $81,637 | $119,275 |
| Operating Income | -$77,233 | -$106,344 | -$169,627 | -$110,143 |
| % Margin | -514% | -654.4% | -1,087.8% | -633% |
| Other Income/Exp. Net | -$30,632 | -$36,446 | -$40,872 | $17,741 |
| Pre-Tax Income | -$107,865 | -$142,790 | -$210,499 | -$91,702 |
| Tax Expense | $671 | $11,468 | -$1,814 | -$1,015 |
| Net Income | -$95,212 | -$139,616 | -$223,692 | -$90,687 |
| % Margin | -633.7% | -859.1% | -1,434.5% | -521.2% |
| EPS | -0.17 | -0.26 | -0.51 | -0.2 |
| % Growth | 34.6% | 49% | -155% | – |
| EPS Diluted | -0.17 | -0.26 | -0.51 | -0.2 |
| Weighted Avg Shares Out | 551,281 | 543,137 | 435,468 | 451,621 |
| Weighted Avg Shares Out Dil | 551,281 | 543,137 | 435,468 | 451,621 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2,668 | $1,132 | $2,219 | $792 |
| Depreciation & Amortization | $5,714 | $4,927 | $3,353 | $4,179 |
| EBITDA | -$99,483 | -$136,731 | -$204,927 | -$86,731 |
| % Margin | -662.1% | -841.4% | -1,314.1% | -498.5% |